Cumulative comorbidity burden does not worsen outcomes in management of chronic rhinosinusitis. Issue 1 (14th July 2021)

• Record Type: Journal Article
• Authors: Gill, Amarbir S.; Mace, Jess C.; Rimmer, Ryan; Ramakrishnan, Vijay R.; Beswick, Daniel M.; Soler, Zachary M.; Manor, James; Orlandi, Richard R.; Smith, Timothy L.; Alt, Jeremiah A.
• Is Part Of: International forum of allergy & rhinology. Volume 12:Issue 1(2022)
• Page Start: 28
• Page End: 38
• Publication Date: 2021-07-14
• Subjects: chronic rhinosinusitis -- patient‐reported outcome measure -- quality of life; 617.51005
• DOI: 10.1002/alr.22866
• Languages: English
• ISSNs: 2042-6976

Abstract

Abstract: Background: The impact of multiple coexisting medical comorbidities on treatment outcomes in chronic rhinosinusitis (CRS) is unknown. In this study we sought to evaluate the effect of comorbidities on sinonasal quality of life (QOL) and general health utility values by utilizing the Functional Comorbidity Index (FCI) in CRS patients. Methods: Patients with CRS were prospectively enrolled in a cross‐sectional study of medical and surgical therapies. The 22‐item Sino‐Nasal Outcome Test (SNOT‐22) and Medical Outcomes Study Short‐Form 6D (SF‐6D) scores were recorded at enrollment and 6‐month follow‐up; Lund‐Kennedy endoscopy and Lund‐Mackay computed tomography scores were recorded at enrollment. The FCI was calculated using the electronic medical record. The impact of cumulative comorbidity burden on baseline and posttreatment outcomes was assessed using univariate and bivariate correlations. Results: A total of 428 participants with CRS were included. The average (mean standard ± deviation) FCI score was 3.03 ± 2.28 (range, 0‐12). Significant linear correlations were identified between increasing FCI score and baseline SNOT‐22 and SF‐6D scores (R = 0.166, p = 0.001 and R = −0.245, p < 0.001, respectively). There was no correlation between FCI and change in SNOT‐22 or SF‐6D scores after CRS treatment (R = 0.066, p = 0.17 and R = −0.087, p = 0.074, respectively). Achievement of a minimally clinically important difference was also independent of FCI. Conclusion: Although cumulative comorbidity burden, as measured by FCI, is associated with worse baseline SNOT‐22 and SF‐6D scores, it does not appear to limit posttreatment improvement in either outcome measure. On average, patients with high comorbidity burden report substantial improvement in both QOL and health utility after CRS treatment, similar to those with fewer comorbidities.